Protagonist Therapeutics (PTGX) Deferred Taxes (2019 - 2020)
Protagonist Therapeutics (PTGX) posted Deferred Taxes of $34000.0 for Q4 2020, up 525.0% sequentially from -$8000.0 in Q3 2020, and down 95.6% YoY from $773000.0 in Q1 2020.
Protagonist Therapeutics (PTGX) Deferred Taxes (2019 - 2020) Analysis & Trends
Protagonist Therapeutics has reported Deferred Taxes for 2 years, with the latest figure at $34000.0 in Q4 2020.
- Quarterly Deferred Taxes fell 95.6% year-over-year to $34000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $1.4 million (up 285.55% YoY) and the FY2020 annual result came in at $1.4 million, up 285.55% from the prior year.
- Deferred Taxes climbed to $34000.0 in Q4 2020 per PTGX's latest filing, from -$8000.0 in the prior quarter.
- Over five years, Deferred Taxes peaked at $1.2 million in Q2 2020 and troughed at -$1.6 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 34,000.00 |
| Sep 30, 2020 | -8,000.00 |
| Jun 30, 2020 | 1.23 Mn |
| Mar 31, 2020 | 183,000.00 |
| Dec 31, 2019 | 773,000.00 |
| Sep 30, 2019 | -102,000.00 |
| Jun 30, 2019 | -1.63 Mn |
| Mar 31, 2019 | 180,000.00 |